SAN FRANCISCO, May possibly 26, 2022 (Globe NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company building therapeutics to sluggish, halt, or reverse health conditions of getting older, today announced that Michael Samar, present chief economical officer at Assembly Bio, has been appointed to the Company’s board of directors as its chair of the audit committee and a member of its compensation committee.
“We’re thrilled to incorporate Michael to UNITY’s board of administrators. With his robust qualifications in biotech finance and operations, merged with an energetic clean viewpoint and keep track of report of execution, Michael’s strategic point of view will be vital as we focus on executing on our UBX1325 reports in DME and AMD and offering vital readouts this calendar year,” claimed Anirvan Ghosh, Ph.D., main government officer of UNITY Biotechnology.
Mr. Samar presently serves as main monetary officer of Assembly Bio, obtaining been promoted from SVP of finance and organization functions. His prior working experience features serving as Vice President of Finance and Web page Head for the South San Francisco facility at Acorda Therapeutics Director of Economical Preparing and Analysis at Onyx Prescribed drugs Senior Finance Director, Global Scheduling and Evaluation at Agennix, and ever more senior roles inside of finance at Johnson & Johnson Pharmaceutical R&D. Mr. Samar attained his MBA from Villanova University and his BS in finance from Bryant College. He also serves as Treasurer on the Board of OUTbio Bay Place, Inc., a non-financial gain organization for LGBTQ+ experts in the biotech and relevant industries.
Concurrent with Mr. Samar’s appointment, Graham K. Cooper has stepped down from the board of administrators.
“Graham has been with UNITY by means of essential components of its evolution and has contributed enormously to the Firm, in particular as Chair of Audit Committee. On behalf of the overall UNITY workforce, I would like to thank him for his focused provider and critical contributions,” reported Keith Leonard, chairman of the board of UNITY Biotechnology. “As we head into the crucial next 50 % of 2022, we appear forward to operating closely with Michael and are delighted to welcome him to our board.”
UNITY is establishing a new class of therapeutics to gradual, halt, or reverse disorders of aging. UNITY’s existing concentrate is on building medications to selectively remove or modulate senescent cells and thereby give transformative benefit in age-related ophthalmologic and neurologic illnesses. More information and facts is offered at www.unitybiotechnology.com or abide by us on Twitter and LinkedIn.
This press release incorporates ahead-hunting statements which includes statements associated to UNITY’s understanding of mobile senescence and the function it performs in illnesses of getting old, the possible for UNITY to establish therapeutics to gradual, halt, or reverse illnesses of growing old, including for ophthalmologic and neurologic conditions, the prospective for UNITY to effectively commence and total clinical reports of UBX1325 for DME, AMD, and other ophthalmologic health conditions, the anticipated timing of enrollment and effects of the clinical trials in UBX1325, and UNITY’s expectations concerning the sufficiency of its income runway. These statements include substantial identified and unidentified hazards, uncertainties, and other components that may possibly bring about our precise success, concentrations of action, general performance, or achievements to be materially various from the details expressed or implied by these ahead-looking statements, such as the risk that the COVID-19 worldwide pandemic could go on to negatively effects the enhancement of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in medical trials, hazards relating to the uncertainties inherent in the drug progress method, and hazards relating to UNITY’s knowledge of senescence biology. We might not essentially accomplish the strategies, intentions, or anticipations disclosed in our forward-wanting statements, and you should really not area undue reliance on our ahead-on the lookout statements. Genuine effects or functions could vary materially from the programs, intentions and anticipations disclosed in the ahead-on the lookout statements we make. The ahead-searching statements in this press release characterize our views as of the day of this release. We foresee that subsequent functions and developments will lead to our sights to modify. Nonetheless, although we could elect to update these ahead-hunting statements at some position in the foreseeable future, we have no recent intention of undertaking so besides to the extent essential by relevant regulation. You ought to, thus, not count on these ahead-wanting statements as representing our sights as of any date subsequent to the day of this release. For a further more description of the risks and uncertainties that could induce real effects to differ from people expressed in these forward-searching statements, as very well as pitfalls relating to the enterprise of UNITY in normal, see UNITY’s most modern Quarterly Report on Kind 10-Q for the quarter ended March 31, 2022, submitted with the Securities and Exchange Commission on May 10, 2022, as well as other documents that may possibly be submitted by UNITY from time to time with the Securities and Exchange Commission.
Media Get hold of:
Supply website link